Roivant Lung Drug Succeeds in Mid-Stage Study
Roivant reported that its experimental drug mosliciguat met the main goals in a mid-stage study for pulmonary hypertension associated with lung disease. The treatment significantly reduced blood vessel resistance and improved patient mobility.
Xurve View
Insights:
Xurve View
Roivant Sciences shares rose 17% Tuesday morning after its experimental lung disease drug met main goals in a 135-patient mid-stage study. The treatment reduced pressure in lung blood vessels by 56.3% compared with placebo over 16 weeks. The milestone expands Roivant's clinical momentum following the U.S. regulatory approval of its skin and muscle disease treatment Lisraya late last month.
